Clinical and pharmacological group: & nbsp
Nootropics
Included in the formulation
АТХ:N.06.B.X Other psychostimulants and nootropic drugs
Pharmacodynamics:Affects GABAB-receptor-channel complex.Strengthens energy processes, increases oxygen consumption of tissues, normalizes blood supply, promotes the utilization of glucose in the brain. Improves thinking, dynamics of nervous processes in the brain, memory, has anticonvulsant activity and anti-anxiety action. Reduces motor excitability, organizes behavior. It causes inhibition of the pathological activity of the cystic reflex and detrusor tone.
Pharmacokinetics:After oral administration, the empty stomach is completely absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is achieved after 1 hour.
Not exposed to metabolism. Penetrates through the blood-brain barrier. Elimination of the kidneys (70%) and feces (30%) unchanged after 48 hours.
Indications:It is used to treat cognitive disorders with organic brain lesions, cerebrovascular insufficiency, extrapyramidal hyperkinesia, including those caused by the administration of neuroleptics. Used in the complex therapy of epilepsy and schizophrenia, with psychoemotional stresses, decreased concentration and memory, neurogenic disorders of urination.
V.F00-F09.F07 Personality and behavioral disorders due to illness, damage or dysfunction of the brain
V.F20-F29.F20 Schizophrenia
V.F40-F48.F43 Reaction to severe stress and adaptation disorders
VI.G10-G13.G10 Huntington's disease
VI.G20-G26.G20 Parkinson's disease
VI.G20-G26.G21 Secondary Parkinsonism
VI.G20-G26.G25.3 Myoclonus
VI.G40-G47.G40 Epilepsy
IX.I60-I69.I67.2 Cerebral atherosclerosis
XIV.N30-N39.N31 Neuromuscular dysfunction of the bladder, not elsewhere classified
XXI.Z70-Z76.Z73.0 Overwork
XXI.Z70-Z76.Z73.3 Stress condition, not elsewhere classified
Contraindications:Acute renal failure, individual intolerance.
Carefully:
Presence of allergic reactions in the anamnesis.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in the first trimester of pregnancy and lactation.
Dosing and Administration: Children
Inside to 1 year: 0.25-0.5 g / day;
1-3 years: 1.5-2 g / day;
3-15 years: 2.5-3 g / day.
Adults
Inside after eating in the morning hours to 0.25-3 g / day.
The highest daily dose: 3 g.
The highest single dose: 3 g.
Side effects:Central and peripheral nervous system: excitement, insomnia or drowsiness, hallucinations.
Dermatological reactions: skin rashes.
Sense organs: rhinitis, conjunctivitis.
Allergic reactions.
Overdose:Increased side effects.
Treatment is symptomatic.
Interaction:Strengthens the effectiveness of anticonvulsants, prolongs the action of barbiturates.
Simultaneous use with glycine and xyliphon enhances the therapeutic effect of the drug.
Prevents side effects of neuroleptics, finlepsin. phenobarbital.
Special instructions:It is not recommended to take the drug in the afternoon and before bedtime.